Nat Med: The efficacy and safety of PD-L1 inhibitor durvalumab combined with platinum + pemetrexed in the treatment of previously untreated and unresectable malignant pleural mesothelioma (MPM): Phase II clinical study PrE0505

Malignant pleural mesothelioma (MPM) is a rare and fatal cancer with limited treatment options until the recently approved immune checkpoint inhibitor combination regimen
.
Recently, Nature Medicine published a magazine II clinical study PrE0505 (NCT02899195) results, mainly to assess the anti- PD-L1 suppression agent durvalumab Plus Platinum + pemetrexed treatment of previously untreated, unresectable malignant pleural mesothelial Efficacy and safety of tumors (MPM) .

Malignant pleural mesothelioma (MPM) is a rare and fatal cancer with limited treatment options until the recently approved immune checkpoint inhibitor combination regimen
.
Recently, Nature Medicine published a magazine II clinical study PrE0505 (NCT02899195) results, mainly to assess the anti- PD-L1 suppression agent durvalumab Plus Platinum + pemetrexed treatment of previously untreated, unresectable malignant pleural mesothelial Efficacy and safety of tumors (MPM) .

Malignant pleural mesothelioma (MPM) is a rare and fatal cancer with limited treatment options until the recently approved immune checkpoint inhibitor combination regimen
.

PrE0505 is a II period, single-arm, multicenter study included previously untreated, unresectable MPM patients (NCT02899195)

.

PrE0505 is a II period, single-arm, multicenter study included previously untreated, unresectable MPM patients (NCT02899195)

In 2017 Nian 6 Yue 12 to 2018 Nian 6 Yue 21 the date, PrE0505 in the United States 15 academic and community cancer centers enrolled 55 patients

All patients were included in the efficacy analysis

OS and PFS

OS and PFS OS and PFS OS and PFS

The objective response rate (ORR) was 56.

4% (95% CI: 42.

The objective response rate (ORR) was 56.

Efficacy evaluation

Efficacy assessment Efficacy assessment

Similarly, compared with patients with non-epithelial MPM, the median OS of patients with epithelioid MPM (24.

3 months vs 9.

Similarly, compared with patients with non-epithelial MPM, the median OS of patients with epithelioid MPM (24.

Comparison of OS and PFS of different pathological types

Comparison of OS and PFS of different pathological types Comparison of OS and PFS of different pathological types

The most frequently reported acute treatment adverse events (TEAE) are mostly low-grade, including fatigue (67%) , nausea (56%), and anemia (56%)

.

The most frequently reported acute treatment adverse events (TEAE) are mostly low-grade, including fatigue (67%) , nausea (56%), and anemia (56%)

In summary, studies have shown that the PD-L1 inhibitor durvalumab combined with platinum + pemetrexed has a significant clinical effect in the treatment of previously untreated and unresectable malignant pleural mesothelioma (MPM)
.
In summary, the research shows that the research shows that the PD-L1 inhibitor durvalumab combined with platinum + pemetrexed has a significant clinical effect in the treatment of previously untreated and unresectable malignant pleural mesothelioma (MPM)
.
The PD-L1 inhibitor durvalumab combined with platinum + pemetrexed has a significant clinical effect in the treatment of previously untreated and unresectable malignant pleural mesothelioma (MPM)
.

Original source:

Original source:

Forde PM, Anagnostou V, Sun Z, et al.
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Nat Med.
2021 Nov 8.
doi: 10.
1038/s41591-021- 01541-0.
Epub ahead of print.
PMID: 34750557.

Forde PM, Anagnostou V, Sun Z, et al.
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Nat Med.
2021 Nov 8.
doi: 10.
1038/s41591-021- 01541-0.
Epub ahead of print.
PMID: 34750557.
Leave a message here